Lord, Abbett & Co
GMAB icon

Lord, Abbett & Co’s Genmab GMAB Stock Holding History

Lord, Abbett & Co’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-645,551
Closed -$27.4M – 590
2022
Q4 		$27.4M Buy
645,551
+475,579
+280% +$19.6M 0.1% 283
2022
Q3 		$5.46M Sell
169,972
-51,113
-23% -$1.79M 0.02% 465
2022
Q2 		$7.18M Buy
221,085
+21,931
+11% +$711K 0.03% 445
2022
Q1 		$7.21M Sell
199,154
-9,908
-5% -$340K 0.02% 511
2021
Q4 		$8.27M Sell
209,062
-5,300
-2% -$221K 0.02% 515
2021
Q3 		$9.37M Sell
214,362
-13,375
-6% -$600K 0.02% 532
2021
Q2 		$9.3M Buy
227,737
+106,606
+88% +$4.11M 0.02% 542
2021
Q1 		$3.98M Buy
+121,131
New +$4.56M 0.01% 597

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Lord, Abbett & Co's GMAB Position: Q1 2023 in Review

Lord, Abbett & Co sold out of Genmab (GMAB) in Q1 2023, closing a stake of 645,551 shares — an estimated $27.4M sold.

Lord, Abbett & Co first reported a position in GMAB in Q1 2021 and held it in 8 quarters. The position peaked at $27.4M in Q4 2022. 216 funds tracked by Wall St. Rank hold GMAB as of Q1 2023.

  • Lord, Abbett & Co reported no remaining Genmab position as of Q1 2023 after selling out during the quarter.
  • Lord, Abbett & Co sold 645,551 Genmab shares in Q1 2023, an estimated $27.4M.
  • Lord, Abbett & Co first reported a position in Genmab in Q1 2021 and held it in 8 quarters.
  • Lord, Abbett & Co's Genmab position peaked at $27.4M in Q4 2022.
  • 216 funds tracked by Wall St. Rank held Genmab as of Q1 2023.

Based on Lord, Abbett & Co's 13F filing for Q1 2023, filed 12 May 2023.